A Clinical Study on the Safety and Efficacy of Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma & Lung Cancer
Latest Information Update: 01 Nov 2024
At a glance
- Drugs REVO UWD 03 (Primary)
- Indications Liver cancer; Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms Wondercel-UWD3
- 29 Oct 2024 Status changed from not yet recruiting to recruiting.
- 29 Oct 2024 New trial record